Literature DB >> 4031268

Interaction of "supplementary" scintigraphic indicators of ischemia and stress electrocardiography in the diagnosis of multivessel coronary disease.

B Canhasi, M Dae, E Botvinick, P Lanzer, N Schechtmann, D Faulkner, W O'Connell, N Schiller.   

Abstract

Lung uptake, ventricular cavitary dilation and basal myocardial uptake represent abnormalities that have been associated with myocardial ischemia on stress thallium-201 images, but that are supplementary to the conventional assessment of perfusion distribution. These "supplementary" indicators of ischemia were related to the coronary distribution of perfusion abnormalities, the results of electrocardiographic stress testing and to the findings on coronary angiography in 73 patients. Forty patients had multivessel coronary disease; 19 of these had three vessel disease. Perfusion abnormalities were seen in 39 of these 40 patients but were indicative of multivessel coronary disease in only 28 and of three vessel disease in only 6. However, supplementary indicators were present in 33 of 40 patients with multivessel disease and in 15 of 19 with three vessel disease. Furthermore, they were seen in 16 of 22 patients with multivessel disease in whom conventional perfusion abnormalities underestimated the extent of disease, but in only 4 of 12 patients in whom the extent of disease was overestimated. The presence of either perfusion abnormalities in a multivessel distribution or supplementary indicators identified 38 (95%) of 40 patients with multivessel disease. A markedly positive electrocardiographic treadmill test was a less sensitive indicator of multivessel disease, appearing in only 15 of 40 patients. However, it was present in only 4 of 33 patients without multivessel coronary disease and was more specific for that diagnosis than were supplementary scintigraphic indicators (88 versus 67%, p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4031268     DOI: 10.1016/s0735-1097(85)80116-9

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  8 in total

1.  Diagnostic value of Tl-201 lung uptake is dependent on measurement method.

Authors:  A Hitzel; A Manrique; A Cribier; P Véra
Journal:  J Nucl Cardiol       Date:  2001 May-Jun       Impact factor: 5.952

2.  Quantification of left ventricular size on exercise thallium-201 single-photon emission tomography.

Authors:  C Kurata; Y Wakabayashi; S Shouda; T Mikami; K Tawarahara
Journal:  Eur J Nucl Med       Date:  1996-07

3.  Comparison of pulmonary uptake with transient cavity dilation after dipyridamole Tl-201 perfusion imaging.

Authors:  Christopher L Hansen; Puxiao Cen; Benjamin Sanchez; Reginald Robinson
Journal:  J Nucl Cardiol       Date:  2002 Jan-Feb       Impact factor: 5.952

4.  Transient left ventricular dilation at quantitative stress-rest sestamibi tomography: clinical, electrocardiographic, and angiographic correlates.

Authors:  C Marcassa; M Galli; C Baroffio; R Campini; P Giannuzzi
Journal:  J Nucl Cardiol       Date:  1999 Jul-Aug       Impact factor: 5.952

Review 5.  Myocardial scintigraphy--25 years after start.

Authors:  G Hör
Journal:  Eur J Nucl Med       Date:  1988

6.  Thallium-201 myocardial scintigraphy in coronary triple-vessel disease: an attempt to increase sensitivity using quantitative methods.

Authors:  M Singer; J Müller-Brand; M E Pfisterer; R Fridrich
Journal:  Eur J Nucl Med       Date:  1987

7.  The ST segment of the ambulatory electrocardiogram in a normal population.

Authors:  R S Kohli; P M Cashman; A Lahiri; E B Raftery
Journal:  Br Heart J       Date:  1988-07

8.  Discordance between dipyridamole stress technetium-99m tetrofosmin single photon emission computed tomography and coronary angiography in patients with Kawasaki disease.

Authors:  Yun-Ching Fu; Yu-Chien Shiau; Shih-Chuan Tsai; Albert Kao; Betau Hwang; Ching-Shiang Chi
Journal:  Int J Cardiovasc Imaging       Date:  2002-10       Impact factor: 2.357

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.